Month: February 2025

– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, Australia and SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$40.0 million via a two tranche placement (the “Placement”) of fully paid ordinary shares (“New Shares”) to Australian and international institutions and other unrelated sophisticated, professional or exempt investors. “We are grateful for the strong response from the investment community and are proud to welcome...

RAMAT GAN, Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on Tuesday, February 25, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Can-Fite Chief Executive Officer Motti Farbstein and Executive Chairperson and Chief Scientific Officer Dr. Pnina Fishman, who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential regulatory and sales milestone payments totaling over $130 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring...

Assays Compilation, Interpretation and Modeling For 83 More Holes Are UnderwayInfographic 1Infographic 1Infographic 2Infographic 2Infographic 3Infographic 3Infographic 4Infographic 4Infographic 5Infographic 5Infographic 6Infographic 6Infographic 7Infographic 7Infographic 8Infographic 8Infographic 9Infographic 9Drilling Highlights:Strong gold mineralization assaying 12.03 g/t AuEq (11.84 g/t Au and 15.61 g/t Ag) over 10.00 meters, including 19.91 g/t AuEq (19.62 g/t Au and 25.61 g/t Ag) over 6.00 meters plus a second separate interval assaying 8.59 g/t AuEq (8.35 g/t Au and 20.74 g/t Ag) over 5.00 meters, including 14.26 g/t AuEq (13.87 g/t Au and 34.10 g/t Ag) over 3.00 meters have been confirmed in an intrusion related feeder dyke that remains open, strongly...

Successfully creates transgenic based on underwater adhesive properties of Caddisfly ANN ARBOR, Mich., Feb. 10, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, proudly announces the successful creation of new novel silk, build upon the silk proteins of the remarkable caddisfly. This breakthrough marks a new frontier in the field of engineered fibers and underscores the Company’s commitment to pioneering innovations in biotechnology.Caddisflies (known in the Pacific Northwest as “Periwinkles”) are known for their extraordinary ability to spin silk underwater, which they use to construct protective cases in aquatic environments. By leveraging the unique mechanical and chemical attributes...

– BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 Trial Design – ALPHARETTA, Ga., Feb. 10, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting. ODYSSEY was a randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week trial evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration (wet AMD). The presentation, entitled “Phase 2b CLS-AX ODYSSEY Trial Results”,...

TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) today announced that Buckreef Gold Limited (“Buckreef Gold”) has entered into its first ever credit agreement with Stanbic Bank Tanzania Limited (“Stanbic”) and a Gold Prepayment Facility with Auramet International, Inc. (“Auramet”). TRX Gold has also renewed its At The Market Offering Agreement (“ATM”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) as Lead Agent and Roth Capital Partners, LLC (“Roth Capital”) as Co-Agent. The combination of these facilities provides the Company with access to supplementary capital, strengthened liquidity, and additional financial flexibility to help accelerate growth in the short to medium term. Credit Facility with Stanbic The credit agreement consists of a $5...

VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) — First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or the “Company”) is pleased to announce that it has entered into an agreement dated February 9, 2025, to issue a $3 million senior unsecured debenture (the “Debenture”) through a non-brokered debt private placement (the “Private Placement”). Closing of the Private Placement remains subject to certain closing conditions, including approval of the TSX Venture Exchange (the “Exchange”). This strategic investment marks a significant milestone for the Company, providing it with a non-dilutive source of capital to support the development of the Company’s district scale Atlantic Nickel Project. The Debenture is the largest individual...

Investment in data centers and associated infrastructure to be delivered by 2030 led by Paris-headquartered Data4 PARIS and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) — At the opening of today’s Artificial Intelligence Action Summit in Paris, Brookfield Asset Management (“Brookfield”), together with the French President, Emmanuel Macron, announced a €20 billion infrastructure investment program to support the deployment of artificial intelligence (“AI”) infrastructure in France. The Brookfield investment will be targeted across data centers and associated infrastructure sectors which are vital for AI deployment. Up to €15 billion of data center investment will be led by Brookfield’s portfolio company, Data4, one of Europe’s largest data center developers, headquartered in Paris. Data4 has existing plans to build over 500 MW of data...

Ontex awarded for disclosure and commitment to environmental transparency and action in 2024, both related to climate and forestry In 2024, Ontex updated its sustainability strategy, with a.o. more ambitious environmental targets related to responsible sourcing, reducing carbon emissions and fossil-based plastics Aalst, Belgium, February 10, 2025 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care products, is proud to announce that it has been awarded an ‘A’ rating by global environmental non-profit organization CDP* for its Climate Change disclosure in 2024 and a ‘A-‘ rating for CDP Forests, for transparency in forestry-related matters. Ontex earned its ‘A’ climate action rating by being transparent about how it emits and actively reduces carbon emissions, sources renewable energy...